Maternus-Kliniken AG (HAM:MAK) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Maternus-Kliniken AG EBITDA Margin % Related Terms
Maternus-Kliniken AG EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Maternus-Kliniken AG's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:MAK vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Maternus-Kliniken AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maternus-Kliniken AG EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Maternus-Kliniken AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Maternus-Kliniken AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maternus-Kliniken AG (HAM:MAK) has a EBITDA Margin % of -4.58% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Maternus-Kliniken AG and its competitors. Over the past decade, Maternus-Kliniken AG's EBITDA Margin % has ranged from 3.45 to 13.54. According to the industry distribution chart, Maternus-Kliniken AG ranks #455 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 68.1%.
Is Maternus-Kliniken AG's EBITDA Margin % too high?
Maternus-Kliniken AG's current EBITDA Margin % is -4.58%. Over the past 10 years, this metric has ranged from a low of 3.45 to a high of 13.54. Based on the distribution chart, Maternus-Kliniken AG ranks #455 out of 668 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Maternus-Kliniken AG has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Maternus-Kliniken AG's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Maternus-Kliniken AG ranks #455 out of 668 companies for EBITDA Margin %. This places Maternus-Kliniken AG in the lower half of its industry. The industry median EBITDA Margin % is 10.21. Historically, Maternus-Kliniken AG's own EBITDA Margin % has ranged from 3.45 to 13.54 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Maternus-Kliniken AG and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maternus-Kliniken AG's current EBITDA Margin % is -4.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maternus-Kliniken AG stock overvalued right now?
Based on GuruFocus' analysis, Maternus-Kliniken AG (HAM:MAK) is currently considered Possible Value Trap. The stock's GF Value™ is €1.72, compared to a current price of €0.92 — trading 46.5% below its estimated fair value. The current EBITDA Margin % is -4.58%. Maternus-Kliniken AG's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Maternus-Kliniken AG (HAM:MAK), the current EBITDA Margin % is -4.58% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maternus-Kliniken AG (HAM:MAK) Overvalued in 2026?
Based on GuruFocus' analysis, Maternus-Kliniken AG stock appears to be undervalued.
The current stock price of €0.92 is trading 46.5% below its estimated GF Value™ of €1.72.
GuruFocus considers Maternus-Kliniken AG to be Possible Value Trap.
Key valuation signals for HAM:MAK:
EBITDA Margin %: -4.58%
GF Value™: €1.72 vs. price of €0.92 (46.5% below fair value)
No single metric tells the full story. See the HAM:MAK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:MAK has been successfully added to your 
